We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Molbio Exhibits Its Novel POC Molecular Platform and Truenat Range of Tests at MEDICA 2021

By LabMedica International staff writers
Posted on 16 Nov 2021

Molbio Diagnostics (Goa, India) exhibited its novel POC Truelab molecular platform and Truenat range of tests at MEDICA 2021, the leading international trade fair for the medical sector. More...

Molbio presented its fully automatic Truelab real time quantitative micro PCR system with a sample to results time of less than one hour. Among the Truelab systems presented at the event was the fully automatic Truelab Uno Dx real time quantitative micro PCR analyzer with a three wavelength system that performs 10-12 tests in eight hours. Molbio also highlighted the fully automatic Truelab Duo real time quantitative micro PCR analyzer with a two channel-three wavelength system that performs 20-24 tests in eight hours, alongside the fully automatic Truelab Quattro real time quantitative micro PCR analyzer with four channel-three wavelength system that performs 40-48 tests in eight hours. Molbio's Truelab also fits in a suitcase that can be transported easily anywhere and used by anyone. The platform can test over 30 diseases with a sample-to-result time of less than an hour, and the results can be transmitted instantly to any place via the IoT enabled platform.

Additionally, Molbio presented its Truenat range of disease-specific real time micro PCR tests at MEDICA 2021. The micro PCR chips are pre-loaded, ready-to-use and disposable. They are disease-specific and can be run on the Truelab Uno Dx/Duo/Quattro to get quantitative real-time PCR results. Among its wide range of Truenat real time micro PCR tests highlighted at the event was Truenat COVID-19, a chip-based RT PCR test for the semi quantitative detection of SARS CoV-2 RNA in human oropharyngeal and nasopharyngeal swab specimen. Molbio also showcased its WHO-endorsed Truenat MTB test for the quantitative detection and diagnosis of Mycobacterium tuberculosis (MTB) in human pulmonary and EPTB specimens that aids in the diagnosis of infection with MTB.

Related Links:
Molbio Diagnostics 


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.